BREAKING NEWS

BREAKING NEWS

Sera Prognostic’s PreTRM Test Featured on Fox 13 News Following Innovation Award Recognition View Fox 13 Story

BREAKING NEWS

Landmark PAPR Published Online in American Journal of Obstetrics & Gynecology View Press Release

PROTEOMIC INNOVATION

“We developed a novel blood test to PREDICT, at an EARLY point in pregnancy, a woman’s individual risk of having a premature baby. We aim to achieve our vision of improving the health of newborns by enabling earlier, effective interventions that make a difference.” Dr. Greg Critchfield, CEO

News

Sera Prognostics to Present at 28th Annual Piper Jaffray Healthcare Conference

November 21, 2016 - Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming 28th Annual Piper Jaffray Healthcare Conference. Dr. Critchfield’s presentation will take place at 11:30 AM ET on Tuesday, November 29th, at the Lotte New York Palace in New York. Read More >

Sera Prognostics’ PreTRM® Test Wins 2016 Utah Innovation Award in Life Sciences

May 12, 2016 – Sera Prognostics, Inc., a women’s health company, today announced that it was selected as the 2016 Utah Innovation Award winner in the Life Science – BioTech category for its novel PreTRM® test, a clinical blood test for early, individualized risk assessment of premature birth. Read More >

Landmark Study Published in American Journal of Obstetrics & Gynecology Validates New Blood Test as Objective, Predictive Tool for Preterm Birth Risk

Clinical validation data from the 5,501 patient Proteomic Assessment of Preterm Risk (PAPR) study were published online in the American Journal of Obstetrics & Gynecology. The article presents the performance in a rigorous clinical validation of Sera’s PreTRM® test for objectively and accurately predicting the risk of spontaneous preterm birth (sPTB) in asymptomatic pregnant women as early as 19 weeks of pregnancy. Read More >

Our Goals

Providing An Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications

Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 9.6% of pregnancies in the U.S. alone.

Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM® Test for Risk Management.